Search results
Results from the WOW.Com Content Network
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies .
William Coley (1862-1936), pioneer of cancer immunotherapy; Albert Coons (1912-1978), developed immunofluorescent techniques for labelling antibodies; Max D. Cooper (1933-), identification of T and B cells; Yehuda Danon (1940-) Deborah Doniach (1912-2004), organ-specific auto-immunity; Eva Engvall (1940-), one of the scientists who invented ...
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology ( immuno-oncology ) and a growing subspecialty of oncology .
1900 – Swedish Dr. Stenbeck cures a skin cancer with small doses of radiation [4]; 1920s – Dr. William B. Coley's immunotherapy treatment, regressed tumors in hundreds of cases, the success of Coley's Toxins attracted heavy resistance from his rival and supervisor, Dr. James Ewing, who was an ardent supporter of radiation therapy for cancer.
1971 – Peter Perlmann and Eva Engvall at Stockholm University invented ELISA; 1972 – Structure of the antibody molecule; 1972 – Discovery of invertebrate immunity by Hans G. Boman [11] 1973 – Dendritic Cells first described by Ralph M. Steinman; 1974 – Immune Network Hypothesis (Niels Jerne)
A British architect invented a bubble helmet in the 1980s to prevent seasonal allergies. He even sold a few hundred of the helmets. (Getty) ... Pham emphasizes that “conventional immunotherapy ...
Talimogene laherparepvec is the world's first approved oncolytic immunotherapy, i.e. it was also designed to provide systemic anti-tumor effects through the induction of an anti-tumor immune response. [citation needed] Talimogene laherparepvec was created and initially developed by BioVex, Inc. under the brand OncoVEX GM-CSF.
They discovered that an immunotherapy cancer drug could block this pathway, restoring function to affected areas of the brain. The findings were recently published in Science .